Prostate Cancer Biomarkers and Their Role in the MRI Era | Urology Grand Rounds скачать в хорошем качестве

Prostate Cancer Biomarkers and Their Role in the MRI Era | Urology Grand Rounds

Recorded live on February 26th, 2024 In this recorded Urology Grand Rounds presentation, Dr. Peter K.F. Chiu, Associate Professor and President of the Hong Kong Biological Association, shares his perspectives on risk stratification of prostate cancer with blood and urine biomarkers and their role in the MRI era from an Asian context. In his lecture, Dr. Chiu highlights the increasing incidence of prostate cancer in Asia and the higher proportion of metastatic disease presentation compared to Western countries. Dr. Chiu delves into various biomarkers, including the Prostate Health Index (PHI), 4K score, PCA3, SelectMDX, Michigan Prostate Score (MPS), XODX, Sentinel, and a urine spermine test developed in Hong Kong. He discusses the performance, advantages, and limitations of these biomarkers, emphasizing the importance of external validation and potential ethnic differences. He also explores the role of these biomarkers in combination with mpMRI findings, aiming to reduce unnecessary biopsies and potentially avoid some mpMRI scans in low-risk patients. Dr. Chiu’s presentation also covers relevant numerical data, such as area under the curve (AUC) values, sensitivity, specificity, and cost considerations for various biomarkers. Claim CE credit at: https://stanford.cloud-cme.com/course... Learning Objectives: 1. Conduct external validation studies for various biomarkers in different ethnic groups to assess their performance and potentially recalibrate reference ranges or cutoffs. 2. Evaluate the cost-effectiveness of incorporating different biomarkers into prostate cancer screening and diagnostic pathways, considering the trade-offs between test costs and potential reductions in unnecessary biopsies or mpMRI scans. 3. Explore the integration of biomarkers with mpMRI findings through prospective studies to develop optimal risk stratification models and decision-making algorithms. 4.Investigate the potential of using biomarkers to identify low-risk patients who may not require mpMRI scans, potentially reducing healthcare costs and resource utilization. 5. Collaborate with international research groups and industry partners to facilitate the development, validation, and widespread availability of promising biomarkers for prostate cancer risk stratification. Mitigation of Relevant Financial Relationships Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education. For full disclosure information, please visit https://stanford.cloud-cme.com/course...